Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
24 Gennaio 2025 - 12:00PM
Business Wire
Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or
“Revelation”), announced today that, on January 28, 2025, the
Company will implement a 1-for-16 reverse split of its common stock
following approval at its Special Meeting of Stockholders held on
January 17, 2025. The reverse stock split will be effective as of
the morning of January 28, 2025, and the Company’s common stock
will trade on a post-split basis at the beginning of trading on the
same date under the existing trading symbol “REVB.” The CUSIP
number for the common stock following the reverse stock split will
be 76135L606.
The reverse stock split is intended to increase the market price
per share of the Company’s common stock to regain compliance with
the minimum bid continued listing requirement of The Nasdaq Capital
Market. Proportionate adjustments will be made to the conversion
and exercise prices of the company’s warrants, restricted stock
unit awards, stock options and to the number of shares issued and
issuable under the Company’s equity incentive plans.
Revelation Bioscience Inc. on January 21st announced the start
of its Prime Phase 1b clinical study of Gemini in CKD patients. The
dosing to commence in Mid-February 2025 and Topline data expected
Mid-Year. For more information on Revelation, please visit
www.RevBiosciences.com.
Information for Stockholders
Upon the effectiveness of the reverse stock split, each sixteen
shares of the Company’s issued and outstanding common stock will be
automatically combined and converted into one issued and
outstanding share of common stock. The reverse stock split will
affect all stockholders uniformly and will not alter any
stockholder’s relative interest in the Company’s equity, except to
the extent that the reverse stock split would have resulted in a
stockholder owning a fractional share. Holders of common stock
otherwise entitled to a fractional share as a result of the Reverse
Stock Split because they hold a number of shares not evenly
divisible by the Reverse Stock Split ratio will be rounded down to
the nearest whole share. The reverse stock split will not change
the par value of the common stock or modify the rights or
preferences of the common stock. The Company’s transfer agent,
Continental Stock Transfer & Trust Co., will maintain the
book-entry records for the Company’s common stock. Registered
stockholders holding pre-split shares of the Company’s common stock
electronically in book-entry form are not required to take any
action to receive post-split shares. Stockholders owning shares via
a broker, bank, trust or other nominee will have their positions
automatically adjusted to reflect the reverse stock split, subject
to such broker’s particular processes, and will not be required to
take any action in connect with the reverse stock split.
Continental Stock Transfer & Trust Co. can be reached at (212)
509-4000 or (800) 509-5586.
About Revelation Biosciences, Inc.
Revelation Biosciences, Inc. is a clinical stage life sciences
company focused on harnessing the power of trained immunity for the
prevention and treatment of disease using its proprietary
formulation Gemini. Revelation has multiple ongoing programs to
evaluate Gemini, including as a prevention for post-surgical
infection, as a prevention for acute kidney injury, and for the
treatment of chronic kidney disease.
For more information on Revelation, please visit www.RevBiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in the Private Securities Litigation Reform Act of 1995, as
amended. Forward-looking statements are statements that are not
historical facts. These forward-looking statements are generally
identified by the words "anticipate," "believe," "expect,"
"estimate," "plan," "outlook," and "project" and other similar
expressions. We caution investors that forward-looking statements
are based on management’s expectations and are only predictions or
statements of current expectations and involve known and unknown
risks, uncertainties and other factors that may cause actual
results to be materially different from those anticipated by the
forward-looking statements. Revelation cautions readers not to
place undue reliance on any such forward-looking statements, which
speak only as of the date they were made. The following factors,
among others, could cause actual results to differ materially from
those described in these forward-looking statements: the ability of
Revelation to meet its financial and strategic goals, due to, among
other things, competition; the ability of Revelation to grow and
manage growth profitability and retain its key employees; the
possibility that the Revelation may be adversely affected by other
economic, business, and/or competitive factors; risks relating to
the successful development of Revelation’s product candidates; the
ability to successfully complete planned clinical studies of its
product candidates; the risk that we may not fully enroll our
clinical studies or enrollment will take longer than expected;
risks relating to the occurrence of adverse safety events and/or
unexpected concerns that may arise from data or analysis from our
clinical studies; changes in applicable laws or regulations;
expected initiation of the clinical studies, the timing of clinical
data; the outcome of the clinical data, including whether the
results of such study is positive or whether it can be replicated;
the outcome of data collected, including whether the results of
such data and/or correlation can be replicated; the timing, costs,
conduct and outcome of our other clinical studies; the anticipated
treatment of future clinical data by the FDA, the EMA or other
regulatory authorities, including whether such data will be
sufficient for approval; the success of future development
activities for its product candidates; potential indications for
which product candidates may be developed; the ability of
Revelation to maintain the listing of its securities on NASDAQ; the
expected duration over which Revelation’s balances will fund its
operations; and other risks and uncertainties described herein, as
well as those risks and uncertainties discussed from time to time
in other reports and other public filings with the SEC by
Revelation.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20250124726986/en/
Company Contacts
Mike Porter Investor Relations Porter LeVay & Rose Inc.
Email: mike@plrinvest.com
Chester Zygmont, III Chief Financial Officer Revelation
Biosciences Inc. Email: czygmont@revbiosciences.com
Grafico Azioni Revelation Biosciences (NASDAQ:REVB)
Storico
Da Dic 2024 a Gen 2025
Grafico Azioni Revelation Biosciences (NASDAQ:REVB)
Storico
Da Gen 2024 a Gen 2025